RE:Question
Idle afternoon thoughts from lay person to lay person.
SABCS San Antonio Breast Cancer Symposium Dec 5-9 2023.
This translational data was presented at the above symposium. It is only right that the company advise its shareholders. I do not see ulterior motives, but from my lay perspective the data seemed compelling. The following caught my eye; increased CD8+ T cell infiltration into - tumors. I believe that is very important.
I do expect that a few posters will enlighten us in the near future. It does support the notion that tecentriq plus pelareorep is a force to be reckoned with. The anal cohort is just tecentriq plus pelareorep, no chemo, just the two.
The could become a multi-pronged (that is to say more than two) Phase 3 outfit.
Holding and hoping.
Best